One To Watch
Candid Therapeutics
Company Overview
A clinical-stage biotechnology company developing novel T-cell engagers for autoimmune and inflammatory diseases, Candid Therapeutics launched in 2024 with $370 million in Series A financing and agreed to a $2.2 billion acquisition by UCB in May 2026. The company has built a focused pipeline of T-cell engager (TCE) assets targeting pathological immune cells in serious autoimmune conditions. Its lead program, cizutamig, is being advanced as a potential best-in-class BCMA-targeted TCE for autoimmune disease indications. Candid sources assets in part through licensing arrangements with Chinese biotechnology companies, combining external innovation with internal clinical development expertise.
Headquarters and Global Presence
Candid Therapeutics is headquartered in San Diego, California, a hub for clinical-stage biotechnology development. As a company launched in September 2024, its operational footprint reflects its early-stage status, centered on its San Diego base with pipeline assets originating through licensing partnerships.
Founding and History
Candid Therapeutics was founded and publicly launched in September 2024, backed by a $370 million Series A financing round — a substantial inaugural raise reflecting investor confidence in the T-cell engager modality for autoimmune disease. The company was built around a strategy of in-licensing differentiated TCE assets from Chinese biotechs and advancing them through clinical development in the United States. In May 2026, less than two years after launch, UCB signed a definitive agreement to acquire Candid for up to $2.2 billion, comprising $2.0 billion upfront and up to $200 million in milestones.
Therapy Areas and Focus
Candid is focused exclusively on autoimmune and inflammatory diseases, a therapeutic space where deeper B-cell and plasma cell depletion strategies are gaining traction. The rationale for targeting BCMA centers on eliminating long-lived plasma cells that drive pathogenic antibody production in conditions such as systemic lupus erythematosus and other severe autoimmune disorders. Standard-of-care treatments for these diseases often fail to achieve durable remission, creating substantial unmet medical need. Candid's pipeline addresses this gap by deploying T-cell engagers engineered to redirect cytotoxic T cells against disease-driving immune cell populations.
Technology Platforms and Modalities
Candid's core platform is built around bispecific T-cell engagers, a class of molecules designed to simultaneously bind a target antigen on pathogenic cells and a T-cell surface protein, redirecting cytotoxic T-cell activity with high precision. The BCMA target is well-validated in oncology, where it has underpinned approved therapies in multiple myeloma, and Candid is translating that biology into autoimmune settings where plasma cell depletion is therapeutically relevant. T-cell engagers offer a potential advantage over broad immunosuppressants by selectively depleting disease-driving cell populations. The company's licensing approach allows it to access next-generation TCE constructs developed externally and accelerate them through the clinic.
Key Pipeline and Programs
Cizutamig is Candid's lead investigational asset, a BCMA-targeted T-cell engager being developed for autoimmune diseases. Positioned as a potential best-in-class agent, cizutamig is designed to engage T cells against BCMA-expressing plasma cells that produce the pathogenic autoantibodies central to diseases such as systemic lupus erythematosus. The asset is in clinical-stage development, building on the established BCMA biology validated in hematologic oncology and applying it to immune-mediated conditions. Candid has indicated it holds two clinical-stage T-cell engager programs in total, with the second asset also targeting autoimmune indications. Both programs were sourced through licensing agreements with Chinese biotechnology companies, reflecting Candid's deliberate strategy of acquiring externally developed clinical assets and advancing them through US and global trials.
Recent Developments
The most material development in Candid's brief history is UCB's agreement to acquire the company, announced May 3, 2026. The deal, valued at up to $2.2 billion — $2.0 billion upfront and $200 million contingent on milestones — gives UCB two clinical-stage T-cell engager programs and strengthens its immunology pipeline. UCB, Belgium's largest drugmaker, positioned the acquisition as a strategic move to build out its autoimmune franchise with novel TCE assets. The transaction was signed as a definitive agreement and was reported by The Pharma Letter on May 5, 2026.
Key Personnel
Ken Song, M.D., serves as Chief Executive Officer of Candid Therapeutics. He previously led RayzeBio as CEO, steering that radiopharmaceutical company to a $4.1 billion acquisition by Bristol Myers Squibb completed in February 2024 — a track record that lent credibility to Candid's large Series A launch. Song brings direct experience building and exiting clinical-stage biotechnology companies focused on novel modalities.
Strategic Partnerships
Candid's pipeline strategy is anchored by licensing agreements with Chinese biotechnology companies, from whom it has in-licensed at least two clinical-stage T-cell engager assets. The May 2026 definitive acquisition agreement with UCB represents the company's most significant strategic transaction, providing up to $2.2 billion in value and a path to full integration into UCB's immunology organization. No other named partnership arrangements have been disclosed.
FAQ Section
UCB, Belgium's largest drugmaker, signed the definitive acquisition agreement on May 3, 2026, paying $2.0 billion upfront and up to $200 million in milestones to secure Candid's two clinical-stage T-cell engager programs. The deal directly strengthens UCB's immunology pipeline at a time when BCMA-directed T-cell engagers are attracting significant pharmaceutical interest for autoimmune indications. UCB framed the acquisition as a strategic priority to build differentiated assets in serious immune-mediated diseases.
BCMA (B-cell maturation antigen) is expressed on long-lived plasma cells, which are responsible for producing the pathogenic autoantibodies that drive many severe autoimmune conditions including systemic lupus erythematosus. In oncology, anti-BCMA therapies have demonstrated potent plasma cell depletion in multiple myeloma, validating the biology at a mechanistic level. Candid's thesis is that the same target can be exploited in autoimmune disease to achieve durable remission by eliminating the immune cells sustaining chronic pathology.
Most approved autoimmune therapies — including JAK inhibitors, anti-CD20 antibodies, and broad immunosuppressants — blunt immune activity systemically or deplete B cells without specifically targeting long-lived plasma cells. Candid's T-cell engagers are designed to redirect cytotoxic T cells directly against BCMA-expressing plasma cells, enabling selective depletion of the antibody-producing cells most responsible for disease. This precision potentially allows deeper and more durable disease control than current standard-of-care approaches.
Cizutamig is Candid's lead investigational asset — a BCMA-targeted T-cell engager developed for autoimmune diseases. It is positioned as a potential best-in-class agent within its class, differentiating on efficacy or tolerability relative to other BCMA-directed bispecifics. The asset is in clinical-stage development, having been in-licensed from a Chinese biotechnology company and advanced under Candid's platform since the company's September 2024 launch.
Candid's pipeline is entirely focused on autoimmune and inflammatory diseases, with both of its clinical-stage T-cell engager programs targeting pathogenic immune cell populations in this space. The company has not disclosed plans to expand into oncology despite the oncology heritage of the BCMA target. This narrow focus reflects a deliberate strategic choice to build depth in immunology rather than breadth across indications.
At the time of UCB's acquisition announcement in May 2026, Candid held two clinical-stage T-cell engager programs, meaning both assets had entered human trials within roughly 18 months of the company's September 2024 launch. The pace of clinical advancement reflects both the $370 million Series A capitalization and the in-licensing strategy, which allowed Candid to acquire assets with existing clinical data packages. Specific trial phase designations and enrollment data for each program were not publicly disclosed ahead of the deal announcement.
With the UCB acquisition agreement signed in May 2026, the principal near-term events center on deal close and pipeline integration. Investors and observers should watch for the following:
Today's issue
| Headless Content Management with Blaze